The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease
Open accessAbstract
BACKGROUND: Alzheimer's disease (AD) is the most common form of dementia. The incidence of AD rises exponentially with age and its prevalence will increase significantly worldwide in the next few decades. Inflammatory processes have been suspected in the pathogenesis of the disease. OBJECTIVES: To review the efficacy and side effects of aspirin, steroidal and non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of AD, compared to placebo. SEARCH METHODS: We searched ALOIS: the Cochrane Dementia and Cognitive Improvement Group's Specialized Register on 12 April 2011 using the terms: aspirin OR "cyclooxygenase 2 inhibitor" OR aceclofenac OR acemetacin OR betamethasone OR celecoxib OR cortisone OR deflazacort OR dexamethasone OR dexibruprofen OR dexketoprofen OR diclofenac sodium OR diflunisal OR diflusinal OR etodolac OR etoricoxib OR fenbufen OR fenoprofen OR flurbiprofen OR hydrocortisone OR ibuprofen OR indometacin OR indomethacin OR ketoprofen OR lumiracoxib OR mefenamic OR meloxicam OR methylprednisolone OR nabumetone OR naproxen OR nimesulide OR "anti-inflammatory" OR prednisone OR piroxicam OR sulindac OR tenoxicam OR tiaprofenic acid OR triamcinolone OR NSAIDS OR NSAID. ALOIS contains records of clinical trials identified from monthly searches of a number of major healthcare databases (including MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS), numerous trial registries (including national, international and pharmacuetical registries) and grey literature sources. SELECTION CRITERIA: All randomised controlled trials assessing the efficacy of aspirin, steroidal and non-steroidal anti-inflammatory drugs in AD. DATA COLLECTION AND ANALYSIS: One author assessed risk of bias of each study and extracted data. A second author verified data selection. MAIN RESULTS: Our search identified 604 potentially relevant studies. Of these, 14 studies (15 interventions) were RCTs and met our inclusion criteria. The numbers of participants were 352, 138 and 1745 for aspirin, steroid and NSAIDs groups, respectively. One selected study comprised two separate interventions. Interventions assessed in these studies were grouped into four categories: aspirin (three interventions), steroids (one intervention), traditional NSAIDs (six interventions), and selective cyclooxygenase-2 (COX-2) inhibitors (five interventions). All studies were evaluated for internal validity using a risk of bias assessment tool. The risk of bias was low for five studies, high for seven studies, and unclear for two studies.There was no significant improvement in cognitive decline for aspirin, steroid, traditional NSAIDs and selective COX-2 inhibitors. Compared to controls, patients receiving aspirin experienced more bleeding while patients receiving steroid experienced more hyperglycaemia, abnormal lab results and face edema. Patients receiving NSAIDs experienced nausea, vomiting, elevated creatinine, elevated LFT and hypertension. A trend towards higher death rates was observed among patients treated with NSAIDS compared with placebo and this was somewhat higher for selective COX-2 inhibitors than for traditional NSAIDs. AUTHORS' CONCLUSIONS: Based on the studies carried out so far, the efficacy of aspirin, steroid and NSAIDs (traditional NSAIDs and COX-2 inhibitors) is not proven. Therefore, these drugs cannot be recommended for the treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972
Diagnostic and Statistical Manual of Mental Disorders
Sciacca, F., Knipe, H., & Sharma, R. (2020) · Radiopaedia.org · doi:10.53347/rid-80880 · Cited by 2,361
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
(2010) · Handbook of Disease Burdens and Quality of Life Measures · doi:10.1007/978-0-387-78665-0_6514 · Cited by 1,385
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Risk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132
Clinical trial of indomethacin in Alzheimer's disease
Rogers, J., Kirby, L. C., Hempelman, S. R., Berry, D. L., McGeer, P. L., Kaszniak, A. W., Zalinski, J., Cofield, M., Mansukhani, L., Willson, P., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1609 · Cited by 999
The incidence of dementia: A meta-analysis
Jorm, A. F., & Jolley, D. (1998) · Neurology · doi:10.1212/wnl.51.3.728 · Cited by 903
The role of inflammation in Alzheimer’s disease
Tuppo, E. E., & Arias, H. R. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.07.009 · Cited by 734
Cyclooxygenase-2: A Therapeutic Target
Turini, M. E., & DuBois, R. N. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103952 · Cited by 683
Ziebell, J. M., & Morganti-Kossmann, M. C. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2009.10.016 · Cited by 667
Baum, L., Lam, C. W. K., Cheung, S. K.-K., Kwok, T., Lui, V., Tsoh, J., Lam, L., Leung, V., Hui, E., Ng, C., et al. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318160862c · Cited by 592
Protective effects of NSAIDs on the development of Alzheimer disease
Vlad, S. C., Miller, D. R., Kowall, N. W., & Felson, D. T. (2008) · Neurology · doi:10.1212/01.wnl.0000311269.57716.63 · Cited by 535
Etminan, M., Gill, S., & Samii, A. (2003) · BMJ · doi:10.1136/bmj.327.7407.128 · Cited by 511
Felson, D. T., Anderson, J. J., Lange, M. L. M., Wells, G., & LaValley, M. P. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199809)41:9 · Cited by 474
Breitner, J. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00049-k · Cited by 466
A randomized controlled trial of prednisone in Alzheimer’s disease
Aisen, P. S., Davis, K. L., Berg, J. D., Schafer, K., Campbell, K., Thomas, R. G., Weiner, M. F., Farlow, M. R., Sano, M., Grundman, M., et al. (2000) · Neurology · doi:10.1212/wnl.54.3.588 · Cited by 464
Immune System Response in Alzheimer's Disease
McGeer, P. L., Akiyama, H., Itagaki, S., & McGeer, E. G. (1989) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100029863 · Cited by 459
Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain
Pasinetti, G. M., & Aisen, P. S. (1998) · Neuroscience · doi:10.1016/s0306-4522(98)00218-8 · Cited by 457
Nonsteroidal anti-inflammatory drugs in Alzheimer's disease
Rich, J. B., Rasmusson, D. X., Folstein, M. F., Carson, K. A., Kawas, C., & Brandt, J. (1995) · Neurology · doi:10.1212/wnl.45.1.51 · Cited by 446
Reuler, J. B., Girard, D. E., & Cooney, T. G. (1985) · New England Journal of Medicine · doi:10.1056/nejm198504183121606 · Cited by 418
A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment
on behalf of the Rofecoxib Protocol 078 study group, Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E., Assaid, C., Nessly, M. L., Norman, B. A., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300690 · Cited by 402
A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease
Scharf, S., Mander, A., Ugoni, A., Vajda, F., & Christophidis, N. (1999) · Neurology · doi:10.1212/wnl.53.1.197 · Cited by 390
Rofecoxib: No effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study
Reines, S. A., Block, G. A., Morris, J. C., Liu, G., Nessly, M. L., Lines, C. R., Norman, B. A., & Baranak, C. C. (2004) · Neurology · doi:10.1212/wnl.62.1.66 · Cited by 385
A randomized controlled trial of prednisone in Alzheimer’s disease
Koch, H. J., & Szecsey, A. (2000) · Neurology · doi:10.1212/wnl.55.7.1067 · Cited by 384
Deeks, J. J., Smith, L. A., & Bradley, M. D. (2002) · BMJ · doi:10.1136/bmj.325.7365.619 · Cited by 369
Solomon, S. D., Wittes, J., Finn, P. V., Fowler, R., Viner, J., Bertagnolli, M. M., Arber, N., Levin, B., Meinert, C. L., Martin, B., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.764530 · Cited by 367
Diener, H.-C., Sacco, R. L., Yusuf, S., Cotton, D., Ôunpuu, S., Lawton, W. A., Palesch, Y., Martin, R. H., Albers, G. W., Bath, P., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70198-4 · Cited by 359
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial
ADAPT Research Group (2007) · Neurology · doi:10.1212/01.wnl.0000260269.93245.d2 · Cited by 354
Salminen, A., Ojala, J., Kauppinen, A., Kaarniranta, K., & Suuronen, T. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.01.001 · Cited by 346
Evidence that Aβ42 is the real culprit in alzheimer's disease
Younkin, S. G. (1995) · Annals of Neurology · doi:10.1002/ana.410370303 · Cited by 333
Inflammatory mechanisms in Alzheimer's disease: implications for therapy
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.8.1105 · Cited by 326
Haass, C., Hung, A. Y., Selkoe, D. J., & Teplow, D. B. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32503-6 · Cited by 317
Reduced incidence of AD with NSAID but not H2receptor antagonists: The Cache County Study
Zandi, P. P., Anthony, J. C., Hayden, K. M., Mehta, K., Mayer, L., & Breitner, J. C. S. (2002) · Neurology · doi:10.1212/wnl.59.6.880 · Cited by 316
An estimate of the total worldwide societal costs of dementia in 2005
Wimo, A., Winblad, B., & Jönsson, L. (2007) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.02.001 · Cited by 300
Wilcock, G. K., Black, S. E., Hendrix, S. B., Zavitz, K. H., Swabb, E. A., & Laughlin, M. A. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70090-5 · Cited by 290
Bazan, N. G. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800068-jlr200 · Cited by 256
Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease
Ho, L., Pieroni, C., Winger, D., Purohit, D. P., Aisen, P. S., & Pasinetti, G. M. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19990801)57:3<295::aid-jnr1>3.0.co;2-0 · Cited by 244
Young, A. H., Sahakian, B. J., Robbins, T. W., & Cowen, P. J. (1999) · Psychopharmacology · doi:10.1007/s002130051057 · Cited by 244
Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: The Cache County Study
Anthony, J. C., Breitner, J. C. S., Zandi, P. P., Meyer, M. R., Jurasova, I., Norton, M. C., & Stone, S. V. (2000) · Neurology · doi:10.1212/wnl.54.11.2066 · Cited by 224
Pharmaceutical Prospects of Phytoestrogens
USUI, T. (2006) · Endocrine Journal · doi:10.1507/endocrj.53.7 · Cited by 210
The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease
Aisen, P. S. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00133-3 · Cited by 203
Randomized Clinical Trial of Daily Aspirin Therapy in Multi‐Infarct Dementia: A Pilot Study
Meyer, J. S., Rogers, R. L., McClintic, K., Mortel, K. F., & Lotfi, J. (1989) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1989.tb05688.x · Cited by 194
Schneider, L., DeKosky, S., Farlow, M., Tariot, P., Hoerr, R., & Kieser, M. (2005) · Current Alzheimer Research · doi:10.2174/156720505774932287 · Cited by 182
The Seminal Role of β-Amyloid in the Pathogenesis of Alzheimer Disease
Joachim, C. L., & Selkoe, D. J. (1992) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199205000-00003 · Cited by 182
Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort
Breitner, J. C. S., Haneuse, S. J. P. A., Walker, R., Dublin, S., Crane, P. K., Gray, S. L., & Larson, E. B. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a18691 · Cited by 179
Randomized pilot study of nimesulide treatment in Alzheimer’s disease
Aisen, P. S., Schmeidler, J., & Pasinetti, G. M. (2002) · Neurology · doi:10.1212/wnl.58.7.1050 · Cited by 176
ADAPT Research Group (2006) · PLoS Clinical Trials · doi:10.1371/journal.pctr.0010033 · Cited by 176
Jiang, Q., Heneka, M., & Landreth, G. E. (2008) · CNS Drugs · doi:10.2165/00023210-200822010-00001 · Cited by 174
Pasqualetti, P., Bonomini, C., Dal Forno, G., Paulon, L., Sinforiani, E., Marra, C., Zanetti, O., & Maria Rossini, P. (2009) · Aging Clinical and Experimental Research · doi:10.1007/bf03325217 · Cited by 172
van Niekerk, J. K., Huppert, F. A., & Herbert, J. (2001) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(01)00014-2 · Cited by 171
Amyloid Deposition and Inflammation in APPswe/PS1dE9 Mouse Model of Alzheimers Disease
Ruan, L., Kang, Z., Pei, G., & Le, Y. (2009) · Current Alzheimer Research · doi:10.2174/156720509790147070 · Cited by 171
Diener, H.-C., Sacco, R., & Yusuf, S. (2007) · Cerebrovascular Diseases · doi:10.1159/000100105 · Cited by 170
Masferrer, J. L., Isakson, P. C., & Seibert, K. (1996) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(05)70252-1 · Cited by 165
Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial
AD Collaborative Group (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70293-4 · Cited by 156
de Jong, D., Jansen, R. W. M. M., Hoefnagels, W. H. L., Mj, J.-E., Verbeek, M. M., Borm, G. F., & Kremer, B. P. H. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001475 · Cited by 151
Widimský, P., Motovska, Z. J., Simek, S., Kala, P., Pudil, R., Holm, F., Petr, R., Bilkova, D., Skalická, H., Kuchynka, P., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn169 · Cited by 147
VITAL Trial Collaborative Group (2003) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01154.x · Cited by 145
Long-Term Efficacy and Safety of Celecoxib in Alzheimer’s Disease
Soininen, H. S., West, C. R., Robbins, J. L., & Niculescu, L. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000096588 · Cited by 144
Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-β aggregation
Thomas, T., Nadackal, T. G., & Thomas, K. (2001) · Neuroreport · doi:10.1097/00001756-200110290-00024 · Cited by 143
Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?
Visser, P. J., Scheltens, P., & Verhey, F. R. J. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.047720 · Cited by 140
Peskind, E. R., Tsuang, D. W., Bonner, L. T., Pascualy, M., Riekse, R. G., Snowden, M. B., Thomas, R. G., & Raskind, M. A. (2005) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000155067.16313.5e · Cited by 134
Szekely, C. A., Green, R. C., Breitner, J. C. S., Østbye, T., Beiser, A. S., Corrada, M. M., Dodge, H. H., Ganguli, M., Kawas, C. H., Kuller, L. H., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000313933.17796.f6 · Cited by 121
Non-Steroidal Anti-Inflammatory Drugs and Alzheimers Disease: The Epidemiological Evidence
Szekely, C. A., & Zandi, P. P. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791012026 · Cited by 116
Chibnall, J. T., Tait, R. C., Harman, B. J., & Luebbert, R. A. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53572.x · Cited by 113
Alzheimer's Disease Anti‐Inflammatory Prevention Trial: Design, methods, and baseline results
ADAPT Research Group (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.09.004 · Cited by 110
Selkoe, D. J. (1991) · Nature · doi:10.1038/354432a0 · Cited by 108
DHEA treatment of Alzheimer’s disease: A randomized, double-blind, placebo-controlled study
Wolkowitz, O. M., Kramer, J. H., Reus, V. I., Costa, M. L., Yaffe, K. S., Walton, P., Raskind, M. A., Peskind, E. R., NEWHOUSE, P. A., Sack, D. A., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000052994.54660.58 · Cited by 101
Ibuprofen Decreases Cytokine-Induced Amyloid Beta Production in Neuronal Cells
Blasko, I., Apochal, A., Boeck, G., Hartmann, T., Grubeck‐Loebenstein, B., & Ransmayr, G. N. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0451 · Cited by 94
Prostaglandin E2 Induces Interleukin‐6 Synthesis in Human Astrocytoma Cells
Fiebich, B. L., Hüll, M., Lieb, K., Gyufko, K., Berger, T., & Bauer, J. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68020704.x · Cited by 93
RS 86 in the treatment of alzheimer's disease: Cognitive and biological effects
Hollander, E., Davidson, M., Mohs, R. C., Horvath, T., Davis, B. M., Zemishlany, Z., & Davis, K. L. (1987) · Biological Psychiatry · doi:10.1016/0006-3223(87)90049-7 · Cited by 91
Walther, S., Schüpbach, B., Seifritz, E., Homan, P., & Strik, W. K. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31820e861c · Cited by 91
Wilcock, G. K. (2003) · UWE Research Repository (UWE Bristol) · Cited by 89
Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study
Yip, A. G., Green, R. C., Huyck, M., Cupples, L. A., Farrer, L. A., & for the MIRAGE Study Group (2005) · BMC Geriatrics · doi:10.1186/1471-2318-5-2 · Cited by 89
Non-steroidal Anti-inflammatory Drugs Stimulate Secretion of Non-amyloidogenic Precursor Protein
Avramovich‐Tirosh, Y., Amit, T., & Youdim, M. B. H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201308200 · Cited by 88
Bernardi, F., Lanzone, A., Cento, R. M., Spada, R. S., Pezzani, I., Genazzani, A. D., Luisi, S. V., Luisi, M., Petraglia, F., & Genazzani, A. (2000) · European Journal of Endocrinology · doi:10.1530/eje.0.1420466 · Cited by 80
Jacobs, L. G., Billett, H. H., Freeman, K. D., Dinglas, C., & Jumaquio, L. (2009) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2009.06.002 · Cited by 77
Evaluation of Selective COX-2 Inhibitors for the Treatment of Alzheimer's Disease
Aisen, P. S. S. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00374-3 · Cited by 75
Nonsteroidal antiinflammatory drug use in Alzheimer's disease
Lucca, U., Tettamanti, M., Forloni, G., & Spagnoli, A. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)90598-3 · Cited by 75
Fotuhi, M., Zandi, P. P., Hayden, K. M., Khachaturian, A. S., Szekely, C. A., Wengreen, H., Munger, R. G., Norton, M. C., Tschanz, J. T., Lyketsos, C. G., et al. (2008) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2008.01.004 · Cited by 71
Boland, B., & Campbell, V. A. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00034-4 · Cited by 71
[Ginkgo biloba extract (EGb 761). State of knowledge in the dawn of the year 2000].
Clostre, F. (1999) · PubMed · Cited by 66
Barton, G. M. (1981) · Annals of Emergency Medicine · doi:10.1016/s0196-0644(81)80290-9 · Cited by 65
Gómez‐Isla, T., Blesa, R., Boada, M., Clarimón, J., del Ser, T., Domènech, G., Ferro, J. M., Gómez‐Ansón, B., Manubens, J. M., Martínez‐Lage, J. M., et al. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181611024 · Cited by 65
Small, G. W., Siddarth, P., Silverman, D. H. S., Ercoli, L. M., Miller, K. J., Lavretsky, H., Bookheimer, S. Y., Huang, S.-C., Barrio, J. R., & Phelps, M. E. (2008) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31818cd3a4 · Cited by 64
Slowing the progression of cognitive decline in alzheimer’s disease using mifepristone
Belanoff, J. K., Jurik, J., Schatzberg, L. D., DeBattista, C., & Schatzberg, A. F. (2002) · Journal of Molecular Neuroscience · doi:10.1007/s12031-002-0033-3 · Cited by 63
O’Shea, T. M., Washburn, L. K., Nixon, P. A., & Goldstein, D. J. (2007) · PEDIATRICS · doi:10.1542/peds.2007-0486 · Cited by 63
Harris, J. R. (2002) · Micron · doi:10.1016/s0968-4328(02)00029-x · Cited by 60
Kimball, A. B., Gold, M. H., Zib, B., & Davis, M. W. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.04.020 · Cited by 58
Leuchtenberger, S., Beher, D., & Weggen, S. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778793029 · Cited by 56
Medication use as a risk factor for falls among hospitalized elderly patients
Walker, P. C., Alrawi, A., Mitchell, J. F., Regal, R. E., & Khanderia, U. (2005) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050116 · Cited by 56
Cognitive performance after cardiac operation: Implications of regression toward the mean
Browne, S. M., Halligan, P. W., Wade, D. T., & Taggart, D. P. (1999) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(99)70327-2 · Cited by 55
Indomethacin and cognitive function in healthy elderly volunteers.
Bruce‐Jones, P., Crome, P., & Kalra, L. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04320.x · Cited by 54
A Pilot Study of Prednisone in Alzheimer's Disease
Aisen, P. S. S., Marin, D. B., Altstiel, L. D., Goodwin, C., Baruch, B., Jacobson, R., Ryan, T. M., & Davis, K. L. (1996) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000106879 · Cited by 52
Indomethacin for Alzheimer's disease
Tabet, N., & Feldman, H. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003673 · Cited by 51
Self-citationLandi, F., Cesari, M., Onder, G., Russo, A., Torre, S., & Bernabei, R. (2003) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200303000-00008 · Cited by 51
A Large, Community-Based, Open-Label Trial of Donepezil in the Treatment of Alzheimer’s Disease
Relkin, N. R., Reichman, W. E., Orazem, J. P., & McRae, T. D. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000069988 · Cited by 48
Clinical Trial Designs for Demonstrating Disease-Course-Altering Effects in Dementia
Whitehouse, P. J., Kittner, B., Roessner, M., Rossor, M. N., Sano, M., Thal, L. J., & Winblad, B. G. (1998) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199812000-00007 · Cited by 47
Effect of High‐Dose Cortisol on Memory Functions
Brunner, R. M., SCHAEFER, D., Hess, K., Parzer, P., Resch, F., & Schwab, S. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1364.037 · Cited by 42
Glucocorticoids in Alzheimer??s Disease: The Story So Far
Aisen, P. S. S., & Pasinetti, G. M. (1998) · Drugs & Aging · doi:10.2165/00002512-199812010-00001 · Cited by 42
Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial
Aisen, P. S. S. (2000) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2000.00312.x · Cited by 40
Steiger, A., Guldner, J., Knisatschek, H., Rothe, B., Lauer, C. J., & Holsboer, F. (1991) · Peptides · doi:10.1016/0196-9781(91)90051-p · Cited by 36
Aisen, P., Thal, L. J., Ferris, S. H., Assaid, C. A., Nessly, M. L., Giuliani, M., Lines, C., Norman, B., & Potter, W. Z. (2008) · Current Alzheimer Research · doi:10.2174/156720508783884602 · Cited by 32
Reversible impaired memory induced by pulsed methylprednisolone in patients with MS
Uttner, I., Müller, S. M., Zinser, C., Maier, M., Süßmuth, S. D., Claus, A., Ostermann, B. M., Elitok, E., Ecker, D., Brettschneider, J., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000163804.94163.91 · Cited by 29
Moretti, R., Torre, P., Antonello, R. M., Cazzato, G., Griggio, S., & Bava, A. (2002) · Current Therapeutic Research · doi:10.1016/s0011-393x(02)80050-9 · Cited by 27
NSAIDs and cognition in Alzheimer's disease
Doraiswamy, P. M., Krishen, A., Stallone, F., Martin, W. L., Potts, N. L. S., Metz, A. L., & DeVeaugh-Geiss, J. (1996) · Neurology · doi:10.1212/wnl.46.4.1194 · Cited by 27
Effect of cortisol levels on working memory performance in elderly subjects with Alzheimer's disease
Souza‐Talarico, J. N., Caramelli, P., Nitríni, R., & Chaves, E. C. (2008) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2008000500003 · Cited by 25
Jin, D., Sung, J., Hwang, Y. K., Kwon, K. J., Han, S., Min, S. S., & Han, J. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.01.016 · Cited by 25
Žerovnik, E. (2010) · Current Alzheimer Research · doi:10.2174/156720510790274437 · Cited by 23
Treatment of the mild cognitive impairment (MCI)
Allain, H., Bentué‐Ferrer, D., & Akwa, Y. (2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.838 · Cited by 22
The prediction and prevention of Alzheimer's disease--towards a research agenda.
van Reekum, R., Simard, M., & Cohen, T. (1999) · PubMed · Cited by 20
Turner, J. W. A. (1958) · BMJ · doi:10.1136/bmj.2.5091.291 · Cited by 19
Wilcock, G. K., Black, S. E., Haworth, J., Hendrix, S. B., Laughlin, M. A., Zavitz, K. H., Christensen, D. D., Bass, S., Swabb, E. A., & MPC-7869 Phase 2 Study Investigators (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.05.316 · Cited by 18
The Effect of Mifepristone (RU 486) on Plasma Cortisol in Alzheimer’s Disease
Pomara, N., Hernando, R. T., Peña, C. B. D. L., Sidtis, J. J., Cooper, T. B., & Ferris, S. H. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9055-5 · Cited by 17
Bertozzi, B., Barbisoni, P., Franzoni, S., Frisoni, G. B., Rozzinia, R., & Trabucchi, M. (1996) · Archives of Gerontology and Geriatrics · doi:10.1016/0167-4943(96)00709-1 · Cited by 16
Wilcock, G. K. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.03.013 · Cited by 15
Pasinetti, G. M. (2002) · Neurosignals · doi:10.1159/000067428 · Cited by 14
A placebo‐controlled screening trial of celecoxib for the treatment of cocaine dependence
Reid, M. S., Angrist, B., Baker, S. A., Woo, C. J., Schwartz, M. P., Montgomery, A., Majewska, D., Robinson, J. A., & Rotrosen, J. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.00989.x · Cited by 14
Approach towards an integrative drug treatment of Alzheimer’s disease
Windisch, M. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6781-6_32 · Cited by 13
Alzheimer Disease: Current Therapy and Future Therapeutic Strategies
Hirai, S. (2000) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200000001-00003 · Cited by 13
Early Stages of Late Onset Alzheimer's Disease
Forssell, L. G., Sjökvist, B., Winblad, B. G., & Forssell, L. G. (1989) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1989.tb04876.x · Cited by 13
Neuroendocrine Responses to Intravenous Infusion of Physostigmine in Patients with Alzheimer Disease
Asthana, S., Raffaele, K. C., Greig, N. H., Schapiro, M. B., Blackman, M. R., & Soncrant, T. T. (1999) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199904000-00008 · Cited by 12
Aisen, P. S. S., Berg, J. D., Craft, S., Peskind, E. R., Sano, M., Teri, L. L., Mulnard, R. A., Thomas, R. G., & Thal, L. J. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00015-x · Cited by 12
Jhee, S. S., Frackiewicz, E. J., Tolbert, D. S., Sainati, S. M., Karim, A., Zolnouni, P., & Choi, K. (2004) · Clinical Research and Regulatory Affairs · doi:10.1081/crp-120030034 · Cited by 8
DHEA treatment of Alzheimer’s disease: A randomized, double-blind, placebo-controlled trial
Leblhuber, F., Haller, H. L., Steiner, K., & Fuchs, D. (2004) · Neurology · doi:10.1212/wnl.62.6.1030 · Cited by 8
Protection against stroke and dementia: An update on the latest clinical trial evidence
Williams, B. (2004) · Current Hypertension Reports · doi:10.1007/s11906-004-0026-4 · Cited by 7
Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5
P1-397 Pioglitazone in Alzheimer's disease: rationale and clinical trial design
Geldmacher, D., & Landreth, G. E. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80709-7 · Cited by 2
Research works printed but not linked: 27
- Zhou, 2004, Effectiveness of polydrug therapy for senile dementia, Chinese Journal of Clinical Rehabilitation, 8, 1214
- Aisen, 2008, Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial, Current Alzheimer Research, 5, 73, 10.2174/156720508783884602 · DOI
- Aizen, 2005, Effect of non-steroidal anti-inflammatory drugs on natural killer cell activity in patients with dementia, The Israel Medical Association Journal, 7, 78
- Jeong, 2004, Therapeutic potentials of mefenamic acid for the treatment of Alzheimer's disease, Neurobiology of Aging, 25, S589, 10.1016/S0197-4580(04)81961-4 · doi:10.1016/s0197-4580(04)81961-4
- Laughlin, 2006, Efficacy and safety of MPC-7869 (R-flurbiprofen), a Selective AB42-Lowering Agent, in Alzheimer's disease (AD): results of a 12-month phase 2 trial and 1-year follow-on study, Journal of the American Geriatrics Society, 54, S7
- Leblhuber F Haller H Steiner K Fuchs D DHEA treatment of Alzheimer's disease: A randomized, double-blind, placebo-controlled trial Neurology 2004 1030 · DOI
- McIntyre, 2006, MPC-7869 - prostate cancer therapy - treatment of Alzheimer's dementia, Drugs of the Future, 31, 22
- Meinert, 2008, Triflusal versus aspirin for the prevention of stroke, Progress in Neurotherapeutics and Neuropsychopharmacology, 3, 13
- Nourhashemi, 1998, Non steroidal anti-inflammatory drugs in Alzheimer disease, Presse Medicale, 27, 25
- Pomara, 1985, Multiple, single-dose naltrexone administrations fail to effect overall cognitive functioning and plasma cortisol in individuals with probable Alzheimer's disease, Neurobiology of Aging, 6, 233, 10.1016/0197-4580(85)90055-7 · doi:10.1016/0197-4580(85)90055-7
- Sainati SM Ingram DM Talwalker S Geis GS Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease Proceedings of the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5-8, Stockholm, Sweden 2000 180
- Simon, 1998, Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor - Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects, Arthritis and Rheumatism, 41, 1591, 10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J · doi:10.1002/1529-0131(199809)41:9<1591::aid-art9>3.0.co;2-j
- Solomon, 2008, Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis, Circulation, 117, 2104, 10.1161/CIRCULATIONAHA.108.764530 · DOI · Paper page
- Stevenson, 2004, A pharmacokinetic, pharmacodynamic, and safety study of celecoxib in subjects with probable Alzheimer's disease, Clinical Research and Regulatory Affairs, 21, 49, 10.1081/CRP-120030034 · DOI
- Stoppe, 1996, Prescribing practice with cognition enhancers in outpatient care: Are there differences regarding type of dementia? Results of a representation survey in lower Saxony, Germany, Pharmacopsychiatry, 29, 150, 10.1055/s-2007-979562 · doi:10.1055/s-2007-979562
- Tsartsalis, 2011, Non-cholinergic pharmacotherapy approaches to Alzheimer's disease: the use of non-steroidal anti-inflammatory drugs, CNS & Neurological Disorders-Drug Targets, 10, 133, 10.2174/187152711794488629 · doi:10.2174/187152711794488629
- Watson, 2004, Rosiglitazone preserves cognitive functions in patients with early Alzheimer's disease, Neurobiology of Aging, 25, 83, 10.1016/S0197-4580(04)80284-7 · doi:10.1016/s0197-4580(04)80284-7
- Wisloff, 1996, Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group, British Journal of Haematology, 94, 324, 10.1046/j.1365-2141.1996.d01-1802.x · doi:10.1046/j.1365-2141.1996.d01-1802.x
- Wollheim, 2000, Selective Cox-2 inhibition in man - therapeutic breakthrough or cosmetic advance?, Rheumatology, 39, 935, 10.1093/rheumatology/39.9.935 · doi:10.1093/rheumatology/39.9.935
- Xia, 2007, Follow-up of a randomized, placebo-controlled trial of dexamethasone to decrease the duration of ventilator dependency in very low birth weight infants: neurodevelopmental outcomes at 4 to 11 years of age, Pediatrics, 120, 594, 10.1542/peds.2007-0486 · DOI
- Yaqub, 1999, New horizons in management of Alzheimer's disease, Saudi Medical Journal, 20, 671
- Zandi, 2005, Pharmacological strategies for prevention of Alzheimer's disease: the epidemiologic evidence, Research and Practice in Alzheimer's Disease, 10, 200
- Zaragoza, 2005, Attitude before COX-2 selective inhibitors, Revista De Investigacion Clinica, 57, 6
- Zhai, 2010, Efficacy observation of batroxobin for treatment of vascular cognitive impairment, Chinese Journal of Cerebrovascular Diseases, 7, 73
- Aisen, 1996, A pilot study of prednisone in Alzheimer's disease, Dementia, 7, 201
- World Health Organisation, 1992, The ICD-10 Classification of Mental and Behavioural disorders: clinical Descriptions and Diagnostic Guidelines
- Wilcock, 2006, Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective Ab42-lowering agent, in Alzheimers disease (AD): Results of a 12-month phase 2 trial and 1-year follow-on study., Alzheimer and Dementia, 2, S81
Cited by
How neuroinflammation contributes to neurodegeneration
Ransohoff, R. M. (2016) · Science · doi:10.1126/science.aag2590 · Cited by 1,967
Neuroinflammation in Alzheimer's disease: current evidence and future directions
Calsolaro, V., & Edison, P. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.010 · Cited by 1,726
Fricker, M., Tolkovsky, A. M., Borutaite, V., Coleman, M., & Brown, G. C. (2018) · Physiological Reviews · doi:10.1152/physrev.00011.2017 · Cited by 1,108
Microglia polarization from M1 to M2 in neurodegenerative diseases
Guo, S., Wang, H., & Yin, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.815347 · Cited by 920
Neuroinflammation: The role and consequences
Lyman, M., Lloyd, D. G., Ji, X., Vizcaychipi, M. P., & Ma, D. (2014) · Neuroscience Research · doi:10.1016/j.neures.2013.10.004 · Cited by 730
Metadata
- Authors
- Jaturapatporn, D., Isaac, M. G. E. K. N., McCleery, J., & Tabet, N.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2012-02-15
- Volume
- 2012
- Issue
- 2
- Pages
- CD006378-CD006378
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2117324900
- Cited by
- 299
- References
- 133
- FWCI
- 18.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.